Active Surveillance

For most men diagnosed with low-risk prostate cancer, the evidence now says the operating room can wait — possibly forever. Fifteen years of randomized follow-up show monitoring matches immediate treatment on survival, with a fraction of the side effects. This page explains what "low-risk" really means, what a surveillance program actually consists of, and the honest psychological cost of choosing to watch.

What "Low-Risk" Actually Means

The surveillance pathway exists because of a biological fact: many prostate cancers are so slow that they will not harm the man who carries them. "Low-risk" is a formal category, not a vibe — guideline definitions (NCCN) require a grade-group 1 tumor (the old Gleason 6, the least aggressive pattern), a PSA under 10, a PSA density below 0.15, a non-palpable tumor, and minimal biopsy involvement. The nomenclature matters: in 2014 the grading system was deliberately renumbered from Gleason 6-of-10 to grade group 1-of-5 partly because a "6 out of 10" sounded like a serious cancer when the biology says otherwise. Even so, the label carries weight — which is why the first job of this pathway is re-education: you were not handed a ticking bomb; you were handed a slow-moving object that a monitoring program can watch. Worth knowing: low-risk disease is the single most common product of PSA screening — it is what most screen-detected diagnoses are — which means this pathway, not the operating room, is the modal destination of modern screening. That is the quiet revolution hidden inside the screening debate.

The ProtecT Numbers

The pivotal evidence is the ProtecT trial, which randomized 1,643 men with localized prostate cancer detected by PSA testing to active monitoring, surgery, or radiotherapy and followed them for fifteen years (Hamdy et al., NEJM, 2023). Prostate-cancer survival was effectively identical across all three arms — the small differences in the chart are statistical noise, not signal. The treated arms bought lower rates of metastasis and disease progression, but they paid for it immediately: in the patient-reported outcomes from the same trial, monitoring men retained sexual and urinary function for years longer, and the quality-of-life gaps between arms narrowed only slowly (Donovan et al., NEJM, 2016). The honest summary: for localized disease, immediate treatment did not buy survival; it bought lower progression risk at the price of real, immediate side effects.

The Anatomy of a Surveillance Plan

Active surveillance is often described by what it is not — "no treatment" — when it is actually a scheduled monitoring program with its own dose, frequency, and escalation rules. The components vary slightly by center, but the skeleton is consistent:

The early confirmatory biopsy is the load-bearing step: roughly a quarter of men initially classified as low-risk are reclassified to a higher grade at that first re-check — usually because the original template biopsy undersampled, not because the cancer changed. That reclassification rate is the reason surveillance programs front-load scrutiny in year one. Modern programs lean on MRI to make those early checks smarter — a stable scan plus a stable PSA can space out the repeat biopsies, which were historically the least pleasant part of the bargain.

When Surveillance Ends

Monitoring converts to treatment on defined triggers, not on feelings: grade progression on a follow-up biopsy (reclassification to grade group 2 with unfavorable features, or grade group 3), substantial increases in tumor volume or core involvement, a steepening PSA trend or rising PSA density, or visible progression on MRI. In ProtecT, roughly three in five monitoring men started treatment within fifteen years — and the critical finding is that this delayed treatment did not appear to forfeit survival. That single sentence is the whole case for the pathway: the men who crossed over were treated roughly when their disease showed its hand, and their outcomes matched the men treated on day one. Crossover is not a failure of surveillance; it is the design working as intended.

Why Immediate Treatment Is Still Right for Some

The same fifteen-year data that exonerate surveillance also define who should not use it. The monitoring arm carried a higher metastasis rate — 9.4% versus about 5% in the treated arms — and for a man who would lose sleep over that gap, treatment is a defensible values-based choice. Higher-risk disease (grade group 2 with volume, grade group 3 and above) sits outside the low-risk definition entirely, and for younger men with intermediate-risk disease the Scandinavian trial evidence suggests surgery does reduce mortality over very long horizons (SPCG-4, Bill-Axelson et al., NEJM, 2018). The honest framing is not "watching is always better" but "watching is equal on survival for low-risk disease, better on side effects early, and not for everyone."

The Psychological Cost, Honestly

The part surveillance brochures underweight is the mental load. Living with a diagnosed, untreated cancer — even one that is almost certainly harmless — is a skill, and a meaningful minority of men on surveillance report persistent cancer-specific anxiety that no amount of statistics fully relieves. Compliance also decays with time: missed appointments and skipped PSAs are the real failure mode of this pathway, because the strategy's safety depends entirely on the schedule being kept. Two honest recommendations follow. First, if the worry itself is the harm, choosing treatment is a legitimate decision — the survival numbers simply should not be the reason. Second, if you choose surveillance, treat the calendar as the treatment: the monitoring is the medicine.

Questions, Answered Briefly

• 🛡️ Is watching really safe? For low-risk disease, fifteen-year randomized data say survival matches immediate treatment. The residual risks are a higher metastasis rate (about 9% vs 5% at 15 years) and the obligation to keep the schedule.
• 🔀 Will I end up treated anyway? Roughly three in five men on surveillance start treatment within fifteen years, usually for grade progression — and the delayed treatment did not appear to cost survival in ProtecT.
• ✅ Am I a candidate? The entry criteria are specific — grade group 1, PSA under 10, low PSA density, minimal biopsy involvement — and the assignment is a clinician's call, not a self-assessment.
• 😰 What if my anxiety is the real problem? Persistent distress is a legitimate reason to choose treatment — quality of life is the endpoint, and peace of mind counts. Just make the choice with the survival numbers above in view, not instead of them.
• 🎯 What about focal therapy? Treating only the lesion rather than the whole gland is under active study, with early results that look interesting but no long-term randomized evidence yet — a conversation with a specialist, not a settled option.

Related Topics